A Phase 2/3 interventional study of HR19034 and HR19034 in Slowing the Progression of Myopia in Children, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 221 studies in Myopia with a site in China — 79 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.
Among the 221 studies in Myopia with a site in China, this one is the 24th largest by enrollment of the 155 interventional ones that give a count, is one of 16 that started in 2021, is the only one in phase 2/3, and was the 217th registered.
1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →79 of the 221 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 123 Myopia studies recruiting now, 19 (15%) set no upper age limit and 103 (84%) stop at 75 or younger; 85 take children under 18; 52 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
221 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 509 is above the median of 79 across 928 interventional studies indexed under Myopia.
Median enrollment 150 across the 155 interventional studies, 1,000 across the 66 observational. Of the 77 that completed or were terminated, 5 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 221 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chengdu Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 7 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
35 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT05850936Sun Yat-sen UniversityEffect of IOP Lowering on Progressive HM | 2026-11-20 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT07008001SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children Extension | 2026-12-31 |
Add all 35 to your calendar (.ics) → With an account.
Among the 221 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the efficacy, and safety of HR19034 Eye Drops. To explore the reasonable dosage of HR19034 for slowing the progression of myopia in children
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Refractive status meets the following conditions:
a) Myopia of 0.5 D (diopters) to 4.00 D (inclusive) in both eyes; B) Astigmatism ≤1.50 D in both eyes; c) Anisometropia ≤1.5 D;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HR19034
Drug: HR19034
Drug: Placebo
HR19034 Dose 1
HR19034 Dose 2
Placebo
Change from baseline in spherical equivalent refraction (SER) measured by cycloplegic autorefraction in the study eye
Time frame: Baseline to Week 96
Change from baseline in spherical equivalent refraction (SER) in the fellow eye
Time frame: Baseline to Week 96
Change from baseline in axial length (AL) in the study eye and fellow eye
Time frame: Baseline to Week 96
Percentage of participants with progression in SER of more than 0.75 D in the study eye and fellow eye
Time frame: Baseline to Week 96
Percentage of participants with progression in SER of more than 0.50 D in the study eye and fellow eye
Time frame: Baseline to Week 96
Percentage of participants with progression in SER of more than 1.00 D in the study eye and fellow eye
Time frame: Baseline to Week 96
Change from baseline in vision-related quality of life
Time frame: Baseline to Week 96
Change from baseline in SER in the study eye and fellow eye
Time frame: Baseline to Week 48
Change from baseline in AL in the study eye and fellow eye
Time frame: Baseline to Week 48
Percentage of participants with progression in SER of more than 0.75 D, 0.50 D and 1.00 D in the study eye and fellow eye
Time frame: Baseline to Week 48
Change from baseline in vision-related quality of life
Time frame: Baseline to Week 48
Change from baseline/Week 96 in SER in the study eye and fellow eye
Time frame: Baseline/Week 96 to Week 120 and 144
Change from baseline/Week 96 in AL in the study eye and fellow eye
Time frame: Baseline/Week 96 to Week 120 and 144
Percentage of participants with progression in SER from Week 96 of more than 0.75 D in the study eye and fellow eye
Time frame: Week 96 to Week 120 and 144]
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Aug 2024, 33 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu Suncadia Medicine Co., Ltd. →